Form 4: Dianthus Therapeutics CEO Marino Garcia Granted Stock Options
SEC Form 4 Filing
Dianthus Therapeutics CEO Marino Garcia was granted stock options to purchase 243,000 shares of common stock on May 23, 2024.
Summary
- Marino Garcia, CEO and President of Dianthus Therapeutics, Inc., was granted stock options on May 23, 2024.
- The stock options allow Garcia to purchase 243,000 shares of Dianthus Therapeutics common stock at an exercise price of $21.77 per share.
- The options vest in equal monthly installments over four years, starting May 1, 2024, contingent upon Garcia's continued service to the company.
- The options expire on May 22, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. Granting stock options is a standard practice that aligns management's interests with shareholders. It suggests confidence in the company's future performance.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Granting stock options to key executives is a common practice in the biotechnology industry to incentivize performance and retain talent. The size and terms of the grant are typical for a CEO of a company of Dianthus's size and stage.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Comparable companies like Argenx and Immunovant also utilize stock options to incentivize their leadership teams.
- The vesting schedule of four years with monthly installments is a common practice to ensure long-term commitment.
Stakeholder Impact
- Shareholders: The stock options incentivize the CEO to increase shareholder value.
- Employees: The grant could boost employee morale by demonstrating confidence in the company's leadership and future.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Start date for monthly vesting of stock options. |
| 05/23/2024 | Date of transaction: Grant of stock options to Marino Garcia. |
| 05/22/2034 | Expiration date of the stock options. |
| 05/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.